|
InterMune, Inc. - Company Profile Snapshot
| Company Profile: |
InterMune, Inc. |
| Ticker: |
ITMN |
| Exchanges: |
NAS |
| 2008 Sales: |
48,152,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
130 |
Business Description
InterMune, Inc.. The Group's principal activity is that of biotech company focused on development and commercialization of innovative therapies in pulmonology and hepatology. It has a product portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Actimmune and Pirfenidone; Actimmune is being evaluated in the INSPIRE Trial, a Phase III and Pirfenidone in the Phase II. The hepatology portfolio includes the lead HCV protease inhibitor PEG-Alfacon-1 in the Phase I, for Chronic Hepatitis C Virus Infections to further expand the limited treatments for HCV infections. The major customers include CuraScript Inc, Caremark, Nova Factor and Merck Medco.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
